A CLINICAL TRIAL FOR HEALTHY 50+ ADULTS
Help Tackle RSV
Learn more about the RSVictory Trial, a clinical trial for a potential new mRNA vaccine to prevent respiratory syncytial virus (RSV) infection.
RSV causes about 177,000 hospitalizations and 14,000 deaths in the U.S. annually in those over the age of 65*
RSV is a common respiratory virus that infects the lungs and breathing passages and is the second leading cause of significant respiratory tract illnesses in adults, behind only influenza (flu).* There are currently no approved treatments or vaccines for RSV.
The RSVictory Trial is studying an investigational vaccine that could help your body’s immune system protect against RSV when given with an approved flu vaccine.
To join the RSVictory Trial, you must be:
✔️50 years of age or older
✔️In good health
Certain chronic diseases such as heart failure and chronic obstructive pulmonary disease may be permissible
✔️Primarily responsible for self-care (do not require a caretaker)
The clinical trial staff will explain additional clinical trial requirements and can answer any questions you may have.
By participating in the RSVictory Trial, you could potentially change the future of RSV.
Reference: *. Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults.Drugs Aging. 2005;22(7):577-587. doi:10.2165/00002512-200522070-00004